Cellares announced a long‑term lease for a new integrated development and manufacturing organization (IDMO) Smart Factory at Leiden Bio Science Park, establishing its European headquarters and regional automated cell therapy capacity. The 9,741‑sq‑meter site will deploy Cellares’ Cell Shuttle automated manufacturing platforms and Cell Q quality control systems once fitted out. Fabian Gerlinghaus, Cellares co‑founder and CEO, cited the facility as a response to regional demand for time‑sensitive, patient‑specific cell therapy production. The site will complement Cellares’ US and Japan capacity to support clinical and commercial supply across geographies. Construction delivery is expected in early 2026, with phased fit‑out and initial occupancy later that year; the move underscores continuing industrialization and regionalization of automated cell therapy manufacturing.